key: cord-1031475-oqe4eunk authors: Xu, Jiuyang; Teng, Yaqun; Shang, Lianhan; Gu, Xiaoying; Fan, Guohui; Chen, Yijun; Tian, Ran; Zhang, Shuyang; Cao, Bin title: The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis date: 2020-10-20 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1592 sha: 9f3051bb92a9b459f2be2ea0c94992131b5961b0 doc_id: 1031475 cord_uid: oqe4eunk There have been arguments on whether angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) treatment alters the risk of COVID-19 susceptibility and disease severity. We identified a total of 102 eligible studies for systematic review, in which 49 studies adjusting for confounders were included in the meta-analysis. We found no association between prior ACEI/ARB use and risk of SARS-CoV-2 infection in general population (adjusted OR [aOR] 1.00, 95% confidence interval [CI] 0.94-1.05). The risk of mortality (aOR 0.87, 95%CI 0.66-1.04) and severe outcomes (aOR 0.95, 95%CI 0.73-1.24) are also unchanged among COVID-19 patients taking ACEI/ARB. These findings remain consistent in subgroup analyses stratified by populations, drug exposures and in other secondary outcomes. This systematic review provides evidence-based support to current medical guidelines and position statements that ACEI/ARB should not be discontinued. Additionally, there has been no evidence for initiating ACEI/ARB regimen as prevention or treatment of COVID-19. The Coronavirus Disease 2019 (COVID- 19) pandemic has been spreading globally, causing hundreds of thousands of deaths and affecting every aspect of human life. Individuals who are older and suffering from underlying cardiovascular and metabolic comorbidities, such as hypertension, coronary artery disease (CAD) and diabetes, are at higher risk to develop severe COVID-19 [1, 2] . The widely used medications for patients with these common comorbidities, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), have raised heated discussions recently regarding their potential effects on the susceptibility to SARS-CoV-2 and severity of COVID-19 [3] [4] [5] [6] [7] . ACEI and ARB are inhibitors of the renin-angiotensin system (RAS), a regulatory system that mediates vasoconstriction, blood pressure elevation, fluid and electrolyte homeostasis, and inflammation through the ACE-AngII-AT1R axis [5, 8, 9] . In animal studies, RAS inhibitors have been shown to increase the tissue expression and activity of ACE2 [10] , which is the homolog for ACE and also the functional receptor for SARS-CoV-2 [11] . These findings lead to concerns that prior ACEI/ARB usage may confer increased susceptibility to SARS-CoV-2 infection [3, 5] . On the other hand, it has been shown that ACE2 can exert protective roles through the ACE2-Ang 1-7 -Mas axis to counterbalance the over-activated ACE-AngII-AT1R axis in the pathogenesis of lung injury and cardiovascular diseases [7, 9, 10] . Diminished ACE2 activity and overactivation of ACE-AngII-AT1R axis also contribute to the progression of cardiovascular diseases and diabetic cardiovascular complication [10] . Therefore, RAS blockade by ACEI/ARB may be protective against severe COVID-19, and is being considered as a potential therapeutic for COVID-19 [3, 10] . Recently, an increasing number of retrospective studies and ongoing clinical trials are investigating the effects of ACEI/ARB on the susceptibility and disease severity of COVID-19 [6, 12] . Although it is widely accepted at this moment that prior ACEI/ARB treatment is not associated with increased susceptibility of SARS-CoV-2 infection [6, 12] , whether they provide additional protection for COVID-19 patients is uncertain, particularly as many of the early studies did not adjust for important confounders [12, 13] . In addition, detailed information is lacking regarding whether the current understanding of the effects of ACEI and/or ARB on COVID-19 can be generalized to different populations and more specific clinical outcomes [13] . In this systematic review, we aim to provide a comprehensive summarization of current evidence We followed the PRISMA statement (see Appendix) and registered the protocol of this systematic review in PROSPERO (CRD42020192898). The eligibility criteria of study inclusion are: 1) Original research investigating the association between prior use of ACEI/ARB and COVID-19 related outcomes. 2) Eligible study designs include randomized controlled trials (RCT), non-randomized clinical trials, cohort studies, and case-control studies. 3) There were no restrictions on languages, publication status or sample size. Exclusion criteria: 1) Reviews, commentaries, in vitro studies, and other non-eligible study designs (geospatial study, etc.). 2) Studies not providing sufficient information to be included in the review after contacting corresponding authors for additional data. and Cochrane COVID-19 study register. We also hand-searched preprint servers (MedRxiv, BioRxiv, SSRN), websites of major publishers/journals, and reference lists of relevant reviews and included studies. We performed the first search on May 26, 2020 and updated the search on July 18, 2020. The search strategy was built based on terms related to COVID-19, ACEI/ARB and hypertension (see Appendix). Two investigators (J.X. and L.S.) independently performed literature screening via Rayyan [14] and Endnote X9 to identify eligible studies. Their disagreements were resolved through discussion with a third investigator (Y.T.). The data extraction and risk of bias assessment were independently performed by two investigators (J.X. and L.S.) and cross-checked by a third investigator (Y.T.). The key components of the data extraction form include author, study design, study location, patient characteristics, event numbers, and summary estimates of effect measures, including adjusted odds ratio (aOR) and adjusted hazard ratio (aHR). We e-mailed the corresponding authors for additional necessary information. The primary outcomes are: 1) testing positive for SARS-CoV-2 via RT-PCR, 2) COVID-19 mortality, and 3) a composite endpoint of severe illness of COVID-19, which include being categorized as severe/critical COVID-19 defined by the authors, requiring ICU admission or A c c e p t e d M a n u s c r i p t 5 mechanical ventilation. The definition for severe/critical disease by authors varied across different studies, but they are generally based on WHO or Chinese national guidelines [15, 16] . The secondary outcomes include individual components of the composite endpoint of severe illness, as well as development of complications including cardiac injury or acute kidney injury (AKI) and duration of hospitalization. Cardiac injury and acute kidney injury were defined as reported previously [17] . We used Cochrane risk-of-bias 2.0 (ROB-2) tool to assess risk of bias for RCT [18] . For observational studies, the relevant Newcastle Ottawa scale (NOS) was used according to the design as case-control or cohort study [19] . Only the data from RCT or observational studies with NOS scored 4 or above were included in the meta-analysis. We used pooled odds ratio (OR) or hazard ratio (HR) with 95% confidence intervals (95% CIs) for dichotomous outcome as summary relative effect measure. For continuous data, standard mean difference (SMD) with 95% CIs was applied, with median and inter quartile range (IQR) converted into mean and standard deviation [20] . The pooled adjusted data were included in the main analysis, and the pooled crude odds ratio were presented in the Supplementary Material. For adjusted outcomes, we calculated the logOR and standard error (SE) from original data and used generic inverse variance method to pool the results. For crude outcomes, we combined original event numbers with Mantel-Haenszel method. Random-effects model is used throughout the meta-analysis considering the potential heterogeneity across different studies. The statistical heterogeneity was assessed using the I² and Q statistic. For the primary outcomes, we performed pre-specified sensitivity analysis by removing (1) pre-print studies, (2) studies with NOS score ≤ 6, (3) potentially overlapping data (if several studies report cases in the same hospitals in overlapped time frame, we reserved data from the study with the largest case number), (4) study including clinically diagnosed patients without nucleic acid test results, (5) each study one by one. We also performed subgroup analyses for the primary outcomes based on study population (geographical locations, cardiovascular comorbidities, etc.) and types of drug exposure (ACEIs and ARBs). We used funnel plot and Egger's test to detect publication bias. Statistical analyses were performed using R package "meta" (version 4.13-0) [21] . For the 102 studies included in the systematic review, there is one RCT, which is an unspecified interim analysis of an on-going RCT initiated before the COVID-19 pandemic evaluating ramipril in treating post-aortic-valve-replacement patients [22] . Table S2) . The RCT was included in the main analysis despite its high risk of bias. The outcome of SARS-CoV-2 infection is available in 24 studies comparing prior ACEI/ARB users versus non-users (23 observational studies and 1 RCT), of which 16 studies providing adjusted measures (aOR or aHR) were included in the meta-analysis ( Table 1) . Prior use of ACEI/ARB is not associated with altered risk of testing positive for SARS-CoV-2 (aOR 1.00, 95%CI 0.94-1.05), nor is the case when ACEI and ARB are evaluated separately (Figure 2 and Figure S3A (Table S3- Next, we sought to analyze the effects of ACEI/ARB on the mortality among COVID-19 patients. Fifty-two studies reported mortality outcome, and the meta-analysis of 20 studies with proper adjustment did not show altered risk for COVID-19 mortality in patients treated with ACEI/ARB measured by aOR (0.87, 95% CI 0.66-1.14) and aHR (0.86, 95% CI 0.66-1.13) (Figure 3 and Table 2 ). Pooled OR directly from crude event numbers reported in 44 studies yielded similar results (OR (Table S3) . Results were unchanged in sensitivity analysis (Figure S4-8) . Notably, we observed a protective effect for ACEI/ARB in the subgroup of COVID-19 patients with cardiovascular diseases (crude OR 0.76, 95%CI 0.60-0.96), but this effect is no longer significant after adjustment (aOR 0.79, 95%CI 0.45-1.40) ( Table S4) . A total of 65 studies reported the composite endpoint of severe outcomes, with 24 of them provided analysis after adjustment for potential confounders (Figure 4 and Table 3 ). Although ACEI/ARB seemed to associate with increased risk of severe outcomes of COVID-19 by pooling crude data (crude OR 1.28, 95% CI 1.06-1.54) (Figure S2C) , the effects of ACEI/ARB remained insignificant in the adjusted studies (aOR 0.95, 95% CI 0.73-1.24) (Figure 4) . The conclusion is not altered in subgroup analysis evaluating ACEI and ARB separately (Figure S3E -F) and stratifying by location or cardiovascular comorbidities (Table S3-4) , as well as in sensitivity analysis as described above (Figure S4-8) . A c c e p t e d M a n u s c r i p t 8 For secondary outcomes, we analyzed the single components of severe disease (severe disease of COVID-19 defined by each included study, ICU admission, and mechanical ventilation) and complications of cardiac and renal injury, and the results are similar to the composite endpoint (Table S5) . Additionally, we evaluated the association between ACEI/ARB usage and hospitalization time of COVID-19. The effects are neutral as shown in the meta-analysis of hospital length of stay and the time from disease onset to hospital discharge ( Figure S9 ). The Crude clinical observations may suggest higher percentage of ACEI/ARB users in those with more severe disease, and in COVID-19 patients compared with the community population. However, this association may be confounded by the fact that increased age and pre-existing hypertension are associated with both ACEI/ARB use and severe COVID-19. Indeed, as pointed out by many original studies, the "association" between prior ACEI/ARB treatment and severe COVID-19 ( Figure S2C ) is no longer significant when evaluating only on data adjusted for age, gender, and other factors ( Figure 4 ). While the concerns for ACEI/ARB use in COVID-19 patients arose, other voices supported ACEI and ARB as candidates for COVID-19 treatment, given that RAS inhibition may counterbalance the effects of ACE2 depletion and mitigate lung injury caused by RAS overactivation. Indeed, several recent reviews have summarized evidences of the protective effects of ACEI/ARB in hypertensive population [23, 24] but not in general COVID-19 patients [25, 26] based on early retrospective studies. However, the majority of these early retrospective studies on ACEI/ARB and COVID-19 were performed without adjustment of age, gender, comorbidities, or concurrent use of A c c e p t e d M a n u s c r i p t 9 other medications (Table S1-2), which may also be potential confounders for this association [13] . Interestingly, our analysis combining crude OR for mortality in COVID-19 patients with pre-existing cardiovascular diseases (mainly hypertension) ( Table S4 ) is in agreement with the protective trend observed in early meta-analysis [23, 24] . However, we cannot detect the "protective" effect of ACEI/ARB in these patients when evaluating data after adjustment of confounders. There are several possible explanations to the diminished protective effects of ACEI/ARB in hypertensive COVID-19 patients after adjustment: 1) The protective trend of ACEI/ARB shown in unadjusted studies is probably due to confounding bias rather than true protective effects. For example, the hypertensive patients who took ACEI/ARB are probably more accessible to medical resources or more compliant to treatments, and thus have better controlled blood pressure and other related cardiovascular and metabolic conditions. Another specific point to be mentioned is that the first line recommendation for elder hypertensive patients in the Chinese guideline is calcium channel blocker (CCB) rather than ACEI/ARB [27] , and therefore patients taking ACEI/ARB are younger than those taking CCBs, presenting as a protective effect of the drugs if age is not adjusted. 2) It may also be that ACEI/ARB is truly protective for COVID-19 patients with hypertension, but the confounders are over-adjusted, or the protective effect is moderate and more studies are needed to achieve statistical significance. Currently, no further judgement can be made based on retrospective observational studies. The only RCT included in this review also points to a neutral effect of ACEI/ARB. Despite the large number of studies published and included in this review, the inherited limitations of retrospective design still prompt RCTs to confirm whether ACEI/ARB indeed has any protective effects on the disease severity of COVID-19. In the early discussions of RAS inhibitors and COVID-19, there are many speculations on the potential difference of ACEI and ARB in COVID-19. It has been proposed that ARB warrant more attention to SARS-CoV-2 infection based on findings that ARB but not ACEI increases ACE2 activity in animal models [28] . Besides, ARBs directly block AT1R but not AngII, and the accumulation of physiological AngII may result in the production of protective peptide Ang 1-7 by ACE2. Therefore, some deduced that ARBs are more favorable as a treatment strategy for COVID-19 [29] . In this review, we concluded that neither drug has effects on susceptibility or severe disease of COVID-19 when evaluated individually (Figure S3) , and there is thus no considerable difference between these two drugs. Another related research update worth mentioning is that treatment of ACEI/ARB does not affect ACE2 level in human plasma [30] . Recent animal studies also confirmed that ACEI/ARB does not alter ACE2 expression in pulmonary tissues [31, 32] . These results indicate that there are still gaps between theoretical deduction and real-world clinical conditions, which must be connected by evidence-based medicine. A c c e p t e d M a n u s c r i p t 10 Our study has several limitations. First, almost all included studies are retrospective observational studies. Second, the definition and criteria of "prior use" of ACEI/ARB is not consistent across studies. Third, we did not address ACEI/ARB continuation versus discontinuation during hospitalization, as the number of studies providing this information is limited at this stage. In conclusion, this review comprehensively summarized the best available evidence that ACEI/ARB should not be discontinued in context of COVID-19 pandemic due to concerns for increased risk of COVID-19 susceptibility or severity. There is currently no evidence for initiating short-term ACEI/ARB as prevention or treatment for COVID-19. This review also provides rationale for evaluating potential protective effect of ACEI/ARB in hypertensive COVID-19 patients with prospective and well-controlled interventional trials. We declare no competing interest. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. M a n u s c r i p t 23 Table 1 for details. Table 2 for details. COVID-19 and Cardiovascular Disease Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19 Angiotensin Converting Enzyme 2: A Double-Edged Sword Renin-angiotensin system and cardiovascular risk Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2 Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review Do the meta-analyses provide a clean bill of health to the use of renin-angiotensin system inhibitors in COVID-19? Rayyan-a web and mobile app for systematic reviews China National Health Commission. Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (Trial Version 5) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China RoB 2: a revised tool for assessing risk of bias in randomised trials The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range How to perform a meta-analysis with R: a practical tutorial Ramipril in High-Risk Patients With COVID-19 Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients? Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19 Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19 Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality Therapy with agents acting on the renin-angiotensin system and risk of SARS-CoV-2 infection Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea Associations with covid-19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study Clinical and Genetic Characteristics of Covid-19 Patients from UK Biobank Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study Non-white ethnicity, male sex, and higher body mass index, but not medications acting on the renin-angiotensin system are associated with coronavirus disease 2019 (COVID-19) hospitalisation: review of the first 669 cases from the UK Biobank Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zheijang Province Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19 in critically ill elderly patients Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19 Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 Comparative Impacts of ACE Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens Association between angiotensin blockade and COVID-19 severity in Hong Kong Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents Pre-Existing Traits Associated with Covid-19 Illness Severity Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors Association between renin-angiotensin system inhibitors and COVID-19 complications Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France Antihypertensive drugs in COVID-19 infection Effetcs of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19 Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19 Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors M a n u s c r i p t Ex # (exposure number), Un # (un-exposure number).* Adjust Hazard Ratio (aHR) is marked with star (*). Otherwise, it is adjusted odds ratio (aOR). A c c e p t e d M a n u s c r i p t